Literature DB >> 9568723

Transgenic mice expressing a truncated Peromyscus leucopus TNF-alpha gene manifest an arthritis resembling ankylosing spondylitis.

M D Crew1, R B Effros, R L Walford, E Zeller, H Cheroutre, E Brahn.   

Abstract

Several studies have implicated tumor necrosis factor-alpha (TNF-alpha) in autoimmune diseases, such as rheumatoid arthritis (RA). To elucidate further the role of TNF-alpha in inflammatory arthritis, we generated transgenic mice harboring a truncated Peromyscus leucopus TNF-alpha (Pe-TNF) gene. An arthritic phenotype closely resembling human ankylosing spondylitis was observed only in transgenic lines expressing the Pe-TNF transgene at the mRNA level. We characterized the arthritic phenotype in detail by radiographic and histologic techniques. It consisted of severe axial skeletal kyphosis and ankylosis, accompanied by an inflammatory and fibrotic process at the end plates and enthesis. Peripheral joint lesions were absent in mice expressing the P. leucopus TNF-alpha gene, in contrast to the RA-like phenotype described in transgenic mice expressing a truncated human TNF-alpha gene. The Pe-TNF transgenic mouse model provides a unique opportunity to explore potential mechanisms whereby TNF-alpha may initiate an autoimmune arthritis resembling ankylosing spondylitis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9568723     DOI: 10.1089/jir.1998.18.219

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  11 in total

Review 1.  Biologic therapies in rheumatoid arthritis.

Authors:  K J Bulpitt
Journal:  Curr Rheumatol Rep       Date:  1999-12       Impact factor: 4.592

Review 2.  Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners.

Authors:  Marcos W Steinberg; Jr-Wen Shui; Carl F Ware; Mitchell Kronenberg
Journal:  Semin Immunopathol       Date:  2009-06-03       Impact factor: 9.623

Review 3.  Experimental spondyloarthropathies: animal models of ankylosing spondylitis.

Authors:  Vyacheslav A Adarichev; Tibor T Glant
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

4.  Serum levels of IL-33 is increased in patients with ankylosing spondylitis.

Authors:  Guo-Wei Han; Li-Wen Zeng; Chun-Xiang Liang; Bai-Ling Cheng; Bing-Sheng Yu; Hao-Miao Li; Fang Fang Zeng; Shao-Yu Liu
Journal:  Clin Rheumatol       Date:  2011-10-04       Impact factor: 2.980

Review 5.  Animal models of ankylosing spondylitis.

Authors:  Yiping Zhang; Shuilang Shi; Christina Ciurli; A Robin Poole
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

Review 6.  Beyond the TNF-α Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology.

Authors:  Susanne Juhl Pedersen; Walter P Maksymowych
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

7.  Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis.

Authors:  Yi Fang; Lu-jin Li; Rui Wang; Feng Huang; Hai-feng Song; Zhong-ming Tang; Yu-zhen Li; Hua-shi Guan; Qing-shan Zheng
Journal:  Acta Pharmacol Sin       Date:  2010-10-18       Impact factor: 6.150

8.  The relationship of serum endocan levels and anti-TNF-alpha therapy in patients with ankylosing spondylitis.

Authors:  Fatma Zehra Kadayıfçı; Makbule Gezmen Karadağ
Journal:  Eur J Rheumatol       Date:  2018-03

9.  Transgenic mice over-expressing carbonic anhydrase I showed aggravated joint inflammation and tissue destruction.

Authors:  Yabing Zheng; Lin Wang; Wei Zhang; Hengwei Xu; Xiaotian Chang
Journal:  BMC Musculoskelet Disord       Date:  2012-12-20       Impact factor: 2.362

10.  Safety and clinical responses in ankylosing spondylitis after three months of etanercept therapy.

Authors:  Chan-Bum Choi; Tae-Jong Kim; Hee-Jin Park; Wan-Sik Uhm; Jae-Bum Jun; Sang-Cheol Bae; Dae-Hyun Yoo; Tae-Hwan Kim
Journal:  J Korean Med Sci       Date:  2008-10       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.